Aim: Several lines of evidence indicate that small dense low-density lipoproteins (sd-LDL) are more atherogenic than large buoyant LDL; however, few prospective studies have addressed the role of sd-LDL in cardiovascular disease (CVD). We therefore examined the association between sd-LDL cholesterol (sd-LDL-C) and CVD in a Japanese cohort. Methods: An 11.7-year prospective study was performed using a general population aged 30-79 without a history of cardiovascular disease. Direct LDL-C and sd-LDL-C were measured in samples from 2034 participants (968 men and 1066 women). Results: During the follow-up period, there were 116 incident cases of CVD. The multivariableadjusted hazard ratios (HRs) of sd-LDL-C for CVD were calculated using a proportional hazards regression model after adjusting for age, hypertension, diabetes, use of lipid-lowering drugs, body mass index, and current smoking and alcohol drinking, and found that increasing quartiles of sd-LDL-C were associated with increased risk of CVD. We also determined that age and sex-adjusted HRs per 10 mg/dL of sd-LDL-C and HRs for CVD, stroke, cerebral infarction, and coronary artery disease were 1.21 (95% CI: 1.12-1.31), 1.17 (95% CI: 1.05-1.30), 1.15 (95% CI: 1.00-1.33), and 1.29 (95% CI: 1.14-1.45), respectively. Conclusions: It was demonstrated that sd-LDL-C was significantly associated with CVD in a Japanese population, providing evidence of sd-LDL-C as an important biomarker to predict CVD. Thromb, 2013; 20:195-203. 
Introduction
The causal relationship between high levels of serum low-density lipoprotein cholesterol (LDL-C) and cardiovascular disease (CVD) has been well established in previous cohort studies [1] [2] [3] [4] [5] . Recent clinical trials have also indicated significant event reduction by statins in the primary and secondary prevention of CVD [6] [7] [8] ; therefore, LDL-C is one of the most important risk factors of CVD and many guidelines, including ours, recommend certain target LDL-C goals for risk management to prevent the development of CVD 5) . Although we use LDL-C as the primary target for cholesterol-lowering therapy, LDL particles are heterogeneous with respect to size and density. Compared to large, buoyant LDL, small dense LDL (sd-LDL) particles exhibit a prolonged plasma residence time, increased penetration into the arterial wall, lower affinity for the LDL receptor, and increased sus-1994, and received medical examinations every 2 years. For these participants, we set the baseline of the present study at medical examinations held between April 1994 and February 1995, since at that time serum samples were collected and stored at −80 ℃. During this period, 2,437 participants attended the medical examination and were followed until the end of 2007. Of these, 403 participants were excluded due to the following reasons: history of CAD or stroke (n = 106), lost to follow-up (n = 132), and other reasons such as missing data (n= 165). Data from the remaining 2,034 participants (968 men and 1,066 women) were included in the analysis. Informed consent was obtained from all participants. This cohort study was approved by the Institutional Review Board of the National Cerebral and Cardiovascular Center.
Baseline Examination
Blood samples were collected after the participants had fasted for at least 10 hours. The samples were centrifuged immediately. Blood pressure was measured in triplicate on the right arm after 5 min of rest by well-trained physicians using a standard mercury sphygmomanometer. The average of the second and third measurements was used for analysis. At baseline examination, subjects were classified into one of the 5 blood pressure categories based on the criteria of ESH-ESC 2007: optimal (SBP ＜120 mmHg and DBP ＜80 mmHg), normal (SBP 120-129 mmHg or DBP 80-84 mmHg), high-normal blood pressure (SBP 130-139 mmHg or DBP 85-89 mmHg), hypertension grade 1 (SBP 140-159 mmHg or DBP 90-99 mmHg), or hypertension grade ≥ 2 (SBP ≥ 160 mmHg or DBP ≥ 100 mmHg). Antihypertensive drug users were classified according to their blood pressure at the baseline survey. Diabetes was defined as fasting serum glucose ≥ 7.0 mmol/L (126 mg/dL) or current use of medications for diabetes. Body mass index (BMI) was calculated as weight (kilograms) divided by height (meters) squared. Well-trained health nurses obtained information on smoking, drinking, and medical histories.
Laboratory Measurements
Serum total cholesterol, triglyceride, and HDL cholesterol (HDL-C) were determined by standard enzymatic methods. Serum glucose was also measured. For the purposes of this study, we used archived plasma samples that had been frozen at −80 ℃ and never previously thawed for the assessment of direct LDL-C and sd-LDL-C by homogeneous methods on a Hitachi 7180 automated analyzer (Hitachi, Tokyo, Japan) 18, 19) . The kits used for these tests (LDL-C and sd-LDL-C) were provided by Denka Seiken (Tokyo, Japan). Assays ceptibility to oxidation 9) . Thus, sd-LDL particles possess elevated atherogenic potential. Furthermore, elevated concentrations of sd-LDL can be found in patients with type 2 diabetes, metabolic syndrome, chronic kidney disease, and familial combined hyperlipidemia [10] [11] [12] [13] [14] , all of which have been found as highly atherogenic conditions. Although Hirano et al. showed that sd-LDL-C is significantly higher in patients with coronary artery disease (CAD) in a cross-sectional study 14) , no prospective study has addressed whether sd-LDL-C can predict a risk for CVD in non-Western populations. Recently, the Québec Cardiovascular Study has shown prospectively that men with an elevated proportion of LDL with a diameter less than 25.5 nm had a 3.6-fold increased risk of CAD compared with men with relatively normal LDL 15) , indicating the strong link of sd-LDL to CVD as a biomarker of cardiovascular disease. Due to its atherogenic properties it is useful to measure sd-LDL for risk assessment; however, a reliable routine method is lacking.
sd-LDL has been measured by ultracentrifugation 16) or gradient gel electrophoresis 17) ; however, these methods are both unsuitable for routine analysis, because each requires expensive equipment, complicated techniques, and long assay times. Hirano et al. have recently developed a simple precipitation method for sd-LDL-C quantification consisting of 2 steps: removal of apolipoprotein B-containing sd-LDL-free lipoproteins by precipitation with heparin and magnesium, followed by LDL-C measurement by the homogeneous method 18, 19) . This assay allowed us to screen sd-LDL-C in a large cohort. Using this assay, Ai et al. recently performed a case control study using samples from the Framingham Offspring Study and found significantly higher sd-LDL-C in women with CAD 20) . Koba et al. also showed that sd-LDL-C is more powerful than LDL-C for the determination of CAD 21) ; however, these are cross-sectional studies and a prospective study is required to determine whether sd-LDL is an independent predictor of CVD. Therefore, the aim of this study was to address the role of sd-LDL-C for incident CVD in a large cohort study in Japan, the Suita study.
Methods

Population
The Suita study, a cohort study on CVD of urban residents, was established in 1989. The details of this study have been described elsewhere 22) . Briefly, 6485 men and women aged 30-79 years underwent a baseline survey at the National Cerebral and Cardiovascular Center between September 1989 and March CVD, we divided the cohort into quartiles according to the basal level of sd-LDL-C. Table 1 shows the clinical characteristics and cardiovascular risk factors of the study population according to the quartiles of sd-LDL-C. BMI, total cholesterol, LDL-C, and triglyceride significantly increased across the sd-LDL-C quartiles both in men and women, while HDL-C decreased in both genders. A significant trend was observed across the quartiles for the severity of high blood pressure, lipid-lowering drug use, and prevalence of diabetes at baseline both in men and women; however, a significant trend for age was only found in women, not in men.
Incidence of CVD According to sd-LDL-C Quartiles
To confirm our previous study, the association between LDL-C and CAD was examined by dividing the cohort into quartiles according to the baseline LDL-C. It was found that age-and multivariableadjusted HRs for CAD were statistically significant only in men, not in women or the total cohort. The HR of the 4th quartile in men was 3.53 (95% confidence intervals (CIs): 1.31-9.54) in an age-adjusted model and 3.56 (95% CIs: 1.28-9.86) in a multivariable-adjusted model, consistent with our previous report 1) . We then performed analysis to examine the effect of sd-LDL-C. During the observation period, 116 cases of CVD, 53 cases of stroke, 36 cases of cerebral infarction, and 63 cases of CAD were reported. As shown in Table 2 , increasing quartiles of sd-LDL-C were significantly associated with increased risks of CVD (stroke＋CAD), stroke, cerebral infarction, and CAD after age and multivariable adjustment. Age and sex-adjusted HRs per 10 mg/dL of sd-LDL-C for CVD, stroke, cerebral infarction, and CAD were 1.21 (95% CI: 1.12-1.31), 1.17 (95% CI: 1.05-1.30), 1.15 (95% CI: 1.00-1.33), and 1.29 (95% CI: 1.14-1.45), respectively. HRs after multivariable adjustment were almost the same. When we analyzed each gender, ageadjusted HRs per 10 mg/dL of sd-LDL-C for CVD, stroke, cerebral infarction, and CAD were significant in women, while those for CVD and CAD were significant in men. HR for CAD of the fourth quartile was almost 4 after age and multivariable adjustment in men.
After putting LDL-C into the multivariable adjusted-models (Model A), sd-LDL-C was still associated with increased risk for CVD, stroke, cerebral infarction, and CAD in the total cohort, for CVD in men, and CVD, stroke, and cerebral infarction in women. After further putting logarithmically transformed triglyceride and HDL-C variables into Model A (Model B), sd-LDL-C was still associated with for direct LDL-C and sd-LDL-C were previously calibrated and directly compared with concentrations obtained after isolation of LDL and sd-LDL by ultracentrifugation.
Endpoint Determination
As previously reported, the endpoints of the present study were (1) date of first CAD or stroke event; (2) date of death; (3) date of leaving Suita city; and (4) the end of December 2007. The first step in the survey for CAD and stroke involved checking the health status of all participants by repeated clinical visits every two years and yearly questionnaires by mail or telephone. In the second step, in-hospital medical records of participants who were suspected of having CAD were reviewed by registered hospital physicians or research physicians who were blinded to the baseline information. The criteria for a diagnosis of CAD included first-ever acute myocardial infarction, sudden cardiac death within 24 h after the onset of acute illness, or coronary artery disease followed by coronary artery bypass surgery or angioplasty. The criteria for definite and probable MI were defined according to the criteria of the MONICA (Monitoring Trends and Determinants of Cardiovascular Disease) project 23) . The criteria for stroke were defined according to the US National Survey of Stroke criteria 24) . Classification of patients into stroke subtypes was based on examination of computed tomography, magnetic resonance imaging, or autopsy.
Statistical Analysis
Continuous variables between groups were compared by analysis of variance and categorical variables were compared by a chi-square test. Triglyceride levels were logarithmically transformed to improve the skewed distribution. The hazard ratio (HR) for MI or stroke was calculated using a proportional hazards model adjusted for age, sex, hypertension (dichotomous variable), diabetes, HDL-C, BMI, smoking (never-smoked; ex-smoker; current smoker) and drinking (never-drank; ex-drinker; regular drinker). All confidence intervals were estimated at the 95% level and significance was set at p＜0.05. All statistical analyses were conducted using the SAS statistical software package (release version 8.2; SAS Institute, Cary, NC, USA).
Results
Baseline Clinical Characteristics According to sd-LDL-C Quartiles
To study the role of sd-LDL in the incidence of 0.056 0.014 TC, total cholesterol; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol. Large LDL-C, LDL-C-Sd-LDL-C. Hypertension was defined as described in methods. Diabetes was defined as fasting serum glucose ≥ 7.0mmol/L (126 mg/dL), the use of antidiabetic agents, or both. 1.16-1.47)  1.29 (1.13-1.48)   1.31 (1.13-1.52)  1.33 (1.12-1.59) study should be performed to define an appropriate cutoff for sd-LDL-C. Because statins, fibrates, and ezetimibe have been shown to reduce the amount of sd-LDL [25] [26] [27] [28] , a randomized control study is required to address whether lowering sd-LDL-C to a certain goal by these drugs can prevent the development of CAD.
In this study we found that sd-LDL-C was significantly associated with traditional risk factors, such as hypertension and diabetes. BMI and the prevalence of diabetes increased and HDL-C decreased across the sd-LDL-C quartiles, and more hypertensive subjects were found in second to fourth quartiles than in the first quartile in both genders. We also found that ageadjusted partial correlation coefficients between sd-LDL-C and BMI, log-transformed triglyceride, LDL-C, and HDL-C (Pearson) were 0.305, 0.636, 0.554, and −0.346 (p＜0.0001), respectively. Thus these data suggest that increased concentrations of sd-LDL-C may be associated with metabolic disorders and that lifestyle modification, such as exercise and weight control, would be effective to reduce sd-LDL in patients with diabetes and metabolic syndrome. Furthermore, we should address whether sd-LDL-C can be used to identify a very high-risk patient with type 2 diabetes, metabolic syndrome, and other metabolic disorders. In contrast to the association with metabolic disorders, an age-related change in sd-LDL-C was found only in women, consistent with the trend of increased atherogenic dyslipidemia in postmenopausal women. Ai et al. also found that postmenopausal women had higher levels of sd-LDL-C than premenopausal women in the Framingham Offspring Study 20) . In addition to type 2 diabetes and metabolic synincreased risks of CVD and stroke in the total cohort and in women, but not in men ( Table 3) .
Discussion
This study clearly indicates an increased risk of CVD, stroke, cerebral infarction, and CAD attributed to elevated sd-LDL-C concentrations in a Japanese population without a previous history of CVD. We also showed that HR was significant after multivariable adjustment and by analysis including LDL-C, log-transformed triglyceride, and HDL-C in the same model. Thus, sd-LDL-C measurement with the new test is promising as a new biomarker to predict the risk of CVD.
In addition to traditional risk factors for CVD, such as hypertension, diabetes, and dyslipidemia, other biomarkers are required to better define the risk and refine therapeutic decisions. There is scientific evidence that sd-LDL particles are highly atherogenic and can be a biomarker of CVD 15, 20, 21) . Our data provide additional evidence to show the role of sd-LDL-C as a CVD risk in the general population. Furthermore, measuring sd-LDL-C with this test has an advantage because it is more user-friendly and more applicable than specialized tests such as gradient gel electrophoresis, nuclear magnetic resonance, and gradient ultracentrifugation.
Until now, there have been no target goals of sd-LDL-C to prevent CAD. In this study the HR of the 4th quartile was statistically significant, suggesting that the cutoff of sd-LDL-C is approximately 50 mg/ dL, although significance was not obtained in women probably due to the low event rate; therefore, a larger (Cont Table 2 familial combined hyperlipidemia, this assay would be quite useful for its diagnosis. Although sd-LDL is decreased by lipid-lowering drugs, such as statins and fibrates, the effect of adequate combination therapy on sd-LDL-C has not yet been confirmed; therefore, this assay would be also useful in determining the therapeutic strategy for patients with a high serum level of sd-LDL-C.
There are some limitations in our study. First, we drome, sd-LDL-C is increased in familial combined hyperlipidemia and postprandial hyperlipidemia 29, 30) . Hirano et al. demonstrated that sd-LDL-C determined by this simple precipitation method is useful for screening familial combined hyperlipidemia in large populations 13) . Because the prevalence of familial combined hyperlipidemia is high in the general population and the increase of sd-LDL particles as well as large VLDL particles is a characteristic feature of Multivariable adjusted for age, sex, body mass index, smoking, drinking, blood pressure category (optimal, normal, and high-normal bloodpressure, hypertension grade 1 and 2＋3), diabetes, and antilipidemic drug user Model A: sd-LDL-C per 10 mg/dL and LDL-C per 10 mg/dL in the same model Model B: sd-LDL-C per 10 mg/dL, LDL-C per 10 mg/dL, ln(TG), and HDL-C per 10 mg/dL in the same model Sd-LDL-C, small dense LDL cholesterol; ln_TG, logarithmical transformed TG Bold numbers: statistically significant used plasma stored at −80 ℃, and there is no guarantee that we would have obtained the same results if we had used fresh serum; however, our results are consistent with those reported by Hirano et al., who measured sd-LDL-C in a Japanese general population with the same method, and comparison studies performed in Japan indicate virtually identical results with the use of fresh vs. frozen plasma for sd-LDL-C 13) . Second, the single measurement of sd-LDL-C at the baseline survey and the fact we did not evaluate the longitudinal trend for each risk factor including lipid-lowering agents may have caused us to underestimate the relationship between these conditions and CAD due to regression dilution bias, although we statistically adjusted for the use of lipid-lowering agents at the baseline survey. Third, serum LDL-C was measured by the direct homogeneous assay, which failed to meet the National Cholesterol Education Program total error goals for diseased individuals, although it met these goals in non-diseased individuals 31) . However, the present study is a cohort study of communitydwelling citizens without a history of CVD. Furthermore, the serum levels of LDL-C determined by direct homogeneous assay are almost consistent with those calculated by the Friedewald formula in a large Japanese cohort.
Conclusions
In this large urban cohort study conducted in Japan, we demonstrated that sd-LDL-C is significantly associated with the development of CVD, providing evidence of sd-LDL-C as an important biomarker to predict CVD. A large intervention study is required to determine the appropriate target level of sd-LDL-C.
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